Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Madrid, Spain. In Hiv Med, Jan 2016
RESULTS: There were 2303 patients from 13 different randomized clinical trials of darunavir/r monotherapy (n = 784: MONET, MONOI, Monarch and PROTEA), lopinavir/r monotherapy (n = 829: OK pilot, OK-04, KalMo, KALESOLO, KRETA, MOST and DREAM), atazanavir/r monotherapy (n = 103: MODAT), or all three (n = 587: PIVOT).
Mepolizumab for eosinophilic severe asthma: recent studies.
London, United Kingdom. In Expert Opin Biol Ther, Jun 2015
EXPERT OPINION: This represents an important new treatment option in an area of unmet need, and together with a large dose ranging study (DREAM) published in 2012 form the basis for filing for registration in the USA and Europe.
Reverse phase protein arrays in signaling pathways: a data integration perspective.
Houston, United States. In Drug Des Devel Ther, 2014
There also exists a clear need for effective visualization approaches to RPPA-based proteomic results; this was highlighted by the recent challenge, put forth by the HPN-DREAM consortium, to develop visualization methods for a highly complex RPPA dataset involving many cancer cell lines, stimuli, and inhibitors applied over time course.
A community computational challenge to predict the activity of pairs of compounds.
New York City, United States. In Nat Biotechnol, 2014
The DREAM consortium launched an open challenge to foster the development of in silico methods to computationally rank 91 compound pairs, from the most synergistic to the most antagonistic, based on gene-expression profiles of human B cells treated with individual compounds at multiple time points and concentrations.
[Closed-Loop at night for the treatment of type 1 diabetes].
Hannover, Germany. In Dtsch Med Wochenschr, 2014
In the multinational, multicenter DREAM project patients at a diabetes camp who were treated with an artificial-pancreas system had less nocturnal hypoglycemia and tighter glucose control than when they were treated with a sensor-augmented insulin pump.